Recent Updates
Recently added Catalysts
ZVRA

KEMPHARM NDRS PRESENTATION 09-21-16

Wednesday, September 21, 2016 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: KEMPHARM NDRS PRESENTATION 09-21-16

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD

Full Press Release Details

KEMPHARM NDRS PRESENTATION 09-21-16.
ShareAdd on Google
Tags: ZVRA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 21, 2016

Biotech snapshot

Cash runway
$260M liquidity · $0M/mo burn
Low dilution risk
Lead asset
KP415Phase 3
ADHD →

Catalyst track record

+71%
best trade around ZVRA's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ZVRA.

See every catalyst's timing & PoA →